News - Events

Taking place in London in September, this event will bring together the ecosystem of the advanced therapies’ industry to promote the opportunities provided by the European market. With 350 attendees and 80-plus speakers from 18 countries as well as 32 exhibitors in attendance, this event will focus on meeting the challenges of managing advanced therapy medicinal products (ATMPs) in this dynamic region. The event is tailored to a European audience looking to commercialise ATMPs as well as a global audience interested in entering the European market.

Chaired by the regulatory expert, Michel Mikhail, this meeting will look at the global market for biosimilar medicines which is expected to grow rapidly with the loss of patent protection for the earliest antibody and protein therapeutics. The biosimilars' market is expected to reach $23.6 billion by 2023, growing at a compound annual rate of 31.7%. Driving this growth are lower prices for these medicines relative to the originator drugs and the ongoing incidence of chronic diseases.

The event will bring together representatives of biorepositories, scientists from the pharmaceutical industry and academics to discuss the management and research applications of biosamples which are reference samples of biological material. The meeting will discuss best practice in biobanking, technical advances in the management of biorepositories, the regulation of biosamples and the role played by international biobank societies.

The conference will explore new technologies and advances in the field of on-body devices which can be used for the administration of viscous and large molecule drugs. It will discuss the relevance of connectivity to the ‘internet of things,’ and ways to enhance the interface between the product and the user. The global wearable devices market size is expected to reach a value of $12.1 billion by 2021.

This meeting will discuss all aspects of maintaining cleanrooms in the context of pharmaceutical development. A cleanroom is a controlled environment where pollutants like dust, airborne microbes and aerosol particles are filtered out. Delegates will learn about cleanroom design and engineering, best practice, regulation and environmental and contamination control. The meeting is also an opportunity to network.

With the number of rare diseases still outnumbering treatments, pharmaceutical companies are continuing to take advantage of regulatory incentives to develop new drugs for these patient populations. Orphan drug incentives available in the US and Europe are therefore of continuing interest. This meeting will discuss the orphan drug market and opportunities for new research. The orphan drug market is expected to reach $176 billion by 2020.

This meeting will bring together clinical researchers, respiratory drug manufacturers and others to discuss current research and developments in drug delivery for respiratory diseases including asthma and chronic obstructive pulmonary disease. It will analyse the success of digital medical devices and connective health technology in aiding the diagnosis of severe asthma and COPD. The meeting will also discuss pulmonary and nasal combination product design.

This conference will explore new technologies in pharmaceutical microbiology and well as the regulatory landscape. Microbiology testing describes the use of biological or biochemical methods to detect impurities in a material. In the context of medicine, it often refers to tests to detect pathogens causing human diseases. This industry is expected to see significant growth over the next five years. At the same time, the technology driving the industry is changing rapidly.